ArticlePsoriasis (Auckland, N.Z.)2022

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study.

Matteo Megna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.